Loading...

ASND

Ascendis Pharma A/S Sponsored ADR · NASDAQ

Performance

+0.01%

1W

+5.6%

1M

-11.36%

3M

+5.52%

6M

+1.51%

YTD

+38.23%

1Y

Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Investment Analysis Report: ASND

Overview

ASND is a pharmaceutical company operating in the Health Technology sector with a market capitalization of $8.49 billion. The company's industry focus is on Pharmaceuticals: Major. In this report, we will conduct a comprehensive analysis of ASND's financial statements over the past three years to evaluat...

See more ...

Technical Analysis of ASND 2024-05-31

Overview:

In analyzing the technical indicators for ASND over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.

Trend Analysis:

  • Moving Averages (MA): The 5-day Moving Average has been consistently above the closin...
See more ...

Recent News & Updates